Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab (MCLA-129) in Advanced NSCLC and Other Solid Tumors
NCT04868877Phase 2Terminated
- Sponsor
- Merus
- Start
- Apr 2021
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of petosemtamab in non-small cell lung cancer (NSCLC), gastric cancer (GC), Esophageal Squamous Cell Carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), sponsored by Merus. Started Apr 2021; status: terminated.
02
Drugs
petosemtamab
03
Conditions
non-small cell lung cancer (NSCLC)gastric cancer (GC)Esophageal Squamous Cell Carcinoma (ESCC)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04868877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868877.